Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

17.01
+1.116.98%
Volume:1.06M
Turnover:18.04M
Market Cap:200.32M
PE:-0.84
High:18.30
Open:18.02
Low:16.27
Close:15.90
52wk High:130.00
52wk Low:6.76
Shares:11.78M
Float Shares:11.47M
Volume Ratio:4.94
T/O Rate:9.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.1806
EPS(LYR):-176.5980
ROE:-64.99%
ROA:-35.94%
PB:0.87
PE(LYR):-0.10

Loading ...

BUZZ-Tonix set for best day in over two months as new fibromyalgia drug hits U.S. market

Reuters
·
Yesterday

Tonix Pharmaceuticals Announces U.S. Commercial Availability of Tonmya™ (Cyclobenzaprine Hcl Sublingual Tablets) as a First-in-Class Fibromyalgia Treatment

THOMSON REUTERS
·
Yesterday

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

GlobeNewswire
·
Yesterday

Tonix Pharmaceuticals Reports Q3 2025 Earnings and Strategic Developments

TIPRANKS
·
Nov 11

Tonix Pharmaceuticals Q3 EPS $(3.59) Misses $(3.58) Estimate, Sales $3.290M Beat $3.100M Estimate

Benzinga
·
Nov 11

Tonix Pharmaceuticals Q3 net loss widens

Reuters
·
Nov 11

Tonix Pharmaceuticals Q3 Net Income USD -32.01 Million

THOMSON REUTERS
·
Nov 11

Tonix Pharmaceuticals - Net Loss $3.59 per Share for Q3 2025

THOMSON REUTERS
·
Nov 11

Tonix Pharmaceuticals - Net Product Revenue for Q3 2025 About $3.3 Mln

THOMSON REUTERS
·
Nov 11

Tonix Pharmaceuticals Holding Corp expected to post a loss of $3.58 a share - Earnings Preview

Reuters
·
Nov 07

Tonix Pharmaceuticals Announces Collaboration With Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-Modified Anti-Cd40l Mab, Tnx-1500, to Prevent Kidney Transplant Organ Rejection

THOMSON REUTERS
·
Nov 04

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

GlobeNewswire
·
Nov 04

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

GlobeNewswire
·
Oct 28

Tonix Pharmaceuticals presents data on Tonmya at ACR Convergence

TIPRANKS
·
Oct 27

BRIEF-Tonix Pharmaceuticals - Prelim Q3 Net Revenue From Product Sales $3.3 Million - SEC Filing

Reuters
·
Oct 27

Tonix Pharmaceuticals - to Launch Tonmya for Fibromyalgia by End of Nov 2025 - SEC Filing

THOMSON REUTERS
·
Oct 27

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

GlobeNewswire
·
Oct 27

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

GlobeNewswire
·
Oct 22

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

GlobeNewswire
·
Oct 21

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

GlobeNewswire
·
Oct 17